Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Cizzle Biotechnology update on development of proprietary antibodies

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has today provided an update on the Company’s progress to develop antibodies for use in its proprietary early lung cancer tests,..

Open Orphan hVIVO to develop the world’s first Omicron human challenge model

Vaxart becomes the first client of the programme to test its oral COVID-19 vaccine candidate Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world..

Goodbody Health undervalued yet good fundamentals (VIDEO)

Goodbody Health Inc. (AQSE:GDBY) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its intention to de-list from the Canadian Securities Exchange and to re-domicile the Company from the Province..

Open Orphan report record revenues and EBITDA-profitability and significant operational progress

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced..

Open Orphan wins £14.7m influenza contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that..

Cizzle Biotechnology annual report now available

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice..

Nuformix provides an update on Company’s assets and other corporate matters

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update on the Company’s assets and other corporate matters. NXP002..

Why is the outlook for Goodbody Health ‘tremendously exciting and hugely positive’ (VIDEO)

Goodbody Health Inc. (CSE: GBDY / AQSE: GBDY / FRA: 484 / OTC: SCNNF) CEO Marc Howells joins DirectorsTalk Interviews to discuss a change of name and direction for the..

Poolbeg Pharma US patents granted for POLB 001 and POLB 002

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been granted patents by the US Patent and Trademark..

Open Orphan due diligence completed by Liberum Capital

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has today announced..

Goodbody Health announces the launch of its Health “MOT” diagnostic test

Goodbody Health (AQSE:GDBY) has announced that it has launched its core UK Health “MOT” test which offers a comprehensive summary of a person’s health. Keenly priced at £99, this new..

Open Orphan to publish full year results on 7 June 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that..

Poolbeg Pharma notify that Schroders PLC increase holding to 5.13%

Poolbeg Pharma plc (LON:POLB) have today announced a TR-1: Notification of major interest in shares. The company published the note stating Schroders PLC now own 25,641,941.00 voting rights, its previous..

Allergy Therapeutics to present at the H.C. Wainwright Global Investment Conference

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that company management will present at the H.C. Wainwright Global Investment Conference being held..

Poolbeg Pharma GMP manufacturing contract signed ensuring ample supply of POLB 001

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced an update on its lead asset, POLB 001,..

Open Orphan key considerations document for developing and manufacturing challenge agents published

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted a..

Cizzle Biotechnology strategic alliance to develop and market early lung cancer detection in USA

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed a heads of terms to partner with CorePath Laboratories, a full service cancer reference..

‘Significant upside from current trading level’ of Goodbody Health says Arden analyst

Goodbody Health Inc. is the topic of conversation when DirectorsTalk Interviews Managing Director Darren Turgel caught up with Colin Smith, Director of Equity Research at Arden & Partners. What has..

Open Orphan no plans to delist, substantial contract with existing top 5 global pharmaceutical client

Comment re: speculation Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials,..

Goodbody Health delivers fantastic revenues 755% higher than 2020

Goodbody Health Inc. ( CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBY ) has announced today a positive adjusted EBITDA of £0.48 million in its audited Financial..

Search

Funds

Health

Search

Funds

Health

FTSE 100

Funds